| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/23/2005 | WO2005005630A3 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 06/23/2005 | WO2005005471A3 Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 06/23/2005 | WO2004113383A3 Pegylated soluble gp130-dimers useful as a medicament |
| 06/23/2005 | WO2004069190A3 Combination therapy for treating protein deficiency disorders |
| 06/23/2005 | WO2004056407A3 Biomedical devices with antimicrobial coatings |
| 06/23/2005 | WO2004052917A3 Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
| 06/23/2005 | WO2004027079A3 Nuclear factor of activated t cells receptor |
| 06/23/2005 | WO2003083078A3 Novel human cell surface protein with immunoglobulin folds, bgs-19 |
| 06/23/2005 | US20050138676 Identification of genes involved in Alzheimer's disease using Drosophila melanogaster |
| 06/23/2005 | US20050137572 Method for infusing insulin to a subject to improve impaired hepatic glucose processing |
| 06/23/2005 | US20050137384 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 06/23/2005 | US20050137329 homodimers of peptide monomers: (AcG)GLYACHMGPIT(1-nal)VCQPLR(MeG)0-1(K)0-1 each containing an intramolecular disulfide bond; spacer N1H (CH2)4 C4H N2H N1 in which N1 is covalently attached via a carbamate or an amide linkage to activated polyethylene glycol moiety; red blood cell production disorders |
| 06/23/2005 | US20050137160 Antisense modulation of cholesteryl ester transfer protein expression |
| 06/23/2005 | US20050137159 Methods compositions and articles of manufacture for modulating bone growth |
| 06/23/2005 | US20050137156 Methods and compositions for generating an immune response |
| 06/23/2005 | US20050137155 RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
| 06/23/2005 | US20050137154 administering human alpha interferon, double-stranded ribonucleic acid (dsRNA) and/or mixtures for the treatment of respiratory system disorders |
| 06/23/2005 | US20050137153 RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
| 06/23/2005 | US20050137142 treating nervous system diorders by administering inhibitors of glutaminyl cyclase and optionally inhibitors of propyl endopeptidases, dipeptidyl aminopeptidases, secretases, endopeptidase, angiotensin converting enzyme and neuropeptide Y receptor ligands, agonists or antagonists; enzyme inhibitors |
| 06/23/2005 | US20050137141 antiviral agents conjugated to amino acids, to enhance bioavailability |
| 06/23/2005 | US20050137140 Peptidomimetic compounds, useful as antiviral agents |
| 06/23/2005 | US20050137139 Peptidomimetic compounds, useful as antiviral agents; used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection |
| 06/23/2005 | US20050137138 E2F activity-inhibiting compound |
| 06/23/2005 | US20050137137 Inhibitors of the Interaction between p53 and MDM2 |
| 06/23/2005 | US20050137136 amino acid sequences which bind to gramnegative bacteria with high specificity, used for identification, detection, and isolation of bacteria, and for the delivery of nucleotides, proteins, toxins, liposomes and drugs to bacteria |
| 06/23/2005 | US20050137135 Novel analogues of glucose-dependent insulinotropic polypeptide |
| 06/23/2005 | US20050137134 administering transforming/nerve growth factors to putamen via catheter connected to inflatable pump; increasing dopaminergic neurons; drug delivery kits |
| 06/23/2005 | US20050137133 nonimmunogenic water soluble polypeptides coupled to hydrophilic polymers, used as thrombopoietin agonist for the treatment of thrombocytopenia; blood disorders |
| 06/23/2005 | US20050137132 Uses of novel potassium channel blockers |
| 06/23/2005 | US20050137131 UspA1 and UspA2 antigens of Moraxella catarrhalis |
| 06/23/2005 | US20050137130 Medical treatment |
| 06/23/2005 | US20050137128 Modulators of ß-amyloid peptide aggregation |
| 06/23/2005 | US20050137127 libraries of macrocyclic peptides used for screening biological targets or drugs; agonists or antagonists of mammal motilin and ghrelin receptors; hormones |
| 06/23/2005 | US20050137126 oligomers of collectins and/or ficolins, such as mannan-binding lectin (MBL), used for prophylaxis and/or treatment of Severe Acute Respiratory Syndrome (SARS); respiratory system disorders |
| 06/23/2005 | US20050137125 concurrent administration of cysteamine hydrochloride with metformin |
| 06/23/2005 | US20050137124 Agents for intravitreal administration to treat or prevent disorders of the eye |
| 06/23/2005 | US20050137123 administering drugs that interacts with genes that code for serum amyloid A (SAA) receptors, the interaction decreases the expression of SAA; gene expression inhibitors; treatment of vision defects |
| 06/23/2005 | US20050137122 Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance |
| 06/23/2005 | US20050137121 Inhibition of invasive remodelling |
| 06/23/2005 | US20050137112 determining lymphocyte epitopes in proteins comprising obtaining from blood, a solution of dendritic cells and CD4 antigens, then promoting cell differentiation, by exposing to cytokines, then mixing with peptides of interest and measuring the proliferation of lymphocytes |
| 06/23/2005 | US20050136523 Catalytic enzyme-modified textiles for active protection from toxins |
| 06/23/2005 | US20050136522 by passivation and adsorption; hydrolase enzyme immobilized within polyelectrolyte multilayers and a polymerizable end-capping layer; storage stable; |
| 06/23/2005 | US20050136515 Nucleotide sequences coding membrane protein for use in identifying modulators for prevention and treatment of cell proliferative, inflammatory, nervous system and autoimmune diseases |
| 06/23/2005 | US20050136514 Related to sodium/glucose cotransporter subfamily; drug screening; biochips; host cells |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136484 Method for screening agents for the treatment of diabetes |
| 06/23/2005 | US20050136482 In vitro methods for determining in vivo thrombotic events |
| 06/23/2005 | US20050136475 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/23/2005 | US20050136467 Neuregulin fusion comprising epidermal growth factor domain for use in treatment and prevention of nervous system and neurodegenerative disorders |
| 06/23/2005 | US20050136436 Double stranded short interfering nucleic acid for use in the treatment of schizophrenia; gene expression inhibition and hairpin loops |
| 06/23/2005 | US20050136435 Amino acid sequences for use in diagnosis, prevention and detection of cancer |
| 06/23/2005 | US20050136430 Inhibitor nucleic acids |
| 06/23/2005 | US20050136422 Neisseria spp. polypeptide, nucleic acid sequence and uses thereof |
| 06/23/2005 | US20050136402 Cancer antigen peptide and/or major histocompatibility complex binding sites for use as tools in detection and tretment of cell proliferative disorders; immunotherapy; genetic vaccine |
| 06/23/2005 | US20050136400 NS3-NS4A protease resistance mutants |
| 06/23/2005 | US20050136129 Administering to postsurgery and/or immobile persons; comprised of proteins, carbohydrates, fats with equivalents of arginine, ascorbic acid and alpha tocopherol |
| 06/23/2005 | US20050136124 Mixing demineralized bone matrix (DBM)with an aqueous solution of a neutral salt and a solubilizer for bone morphogenic proteins (BMP) to liquefy; assaying BMP by enzyme-linked immunosorbent assay to determine osteoinductivity without dialysis |
| 06/23/2005 | US20050136121 Melting lipid, dry mixing dry particles comprising filler and peptide; suspension; continuously coating; pseudoplastic and/or thixotropic properties; pouring or molding into a dosage form |
| 06/23/2005 | US20050136091 Crosslinkable macromers |
| 06/23/2005 | US20050136088 Upper respiratory infections, skin infections, wounds, and burns, vaginal infections, eye infections, intestinal disorders and dental problems |
| 06/23/2005 | US20050136076 Immunogenic detoxified mutants of cholera toxin |
| 06/23/2005 | US20050136074 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy |
| 06/23/2005 | US20050136069 Immunogenic portion of Mycobacterium tuberculosis proteins and monophosphoryl lipid A as adjuvant; vaccines |
| 06/23/2005 | US20050136068 Enzymatically inactive streptococcal C5a peptidase (SCP) conjugated or linked to one or more peptides; effective in immunizing a susceptible mammal against beta-hemolytic Streptococcus |
| 06/23/2005 | US20050136066 Providing autologous target diseased cell, treating to increase the levels of one or more primary and costimulatory T cell activation molecules in target diseased cell, attaching bridge molecule to diseased cell, collecting bridged cells |
| 06/23/2005 | US20050136058 Insulin-like growth factor binding protein (IGFBP-5) |
| 06/23/2005 | US20050136057 Chimeric L chain comprising an L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein; may be used widely in hypercalcemia associated with various cancers |
| 06/23/2005 | US20050136054 Humanised antibodies |
| 06/23/2005 | US20050136046 Methods of using therapeutic fibrinogen compositions |
| 06/23/2005 | US20050136045 Can be administered by continuous infusion or by single intravenous bolus injection; use in the treatment of arterial thrombosis and for treating myocardial infarction; reduced antigenicity and immunogenicity as compared to wild-type staphylokinase |
| 06/23/2005 | US20050136044 Exhibit increased ability to convert chemotherapeutic agent pro-drugs into active drugs; provide treatment options for cancer |
| 06/23/2005 | US20050136043 Transforming Growth Factor (TGF); peptide that inhibits TGF beta signaling and/or Smad2 phosphorylation; mimetics; use with known enzyme inhibitors such as pyridinylimidazole drugs SB203580, SB202190, SB202474, PD169316, and SC68376; use e.g. treating tumors |
| 06/23/2005 | US20050136041 Transgenic cell comprising nucleotide sequences coding erythropoietin and/or glucagon-like peptides for use in treatment and prevention of blood and metabolic disorders; somatic and germ cell gene therapy; tissue engineering |
| 06/23/2005 | US20050136034 Uses of IL-12 in hematopoiesis |
| 06/23/2005 | US20050136033 Administering chimeric polypeptide with a domain that binds to a chemokine receptor and another domain that binds to one of the following: a T cell surface polypeptide, a dendritic cell surface polypeptide, a cell toxin; allergic asthma; kits |
| 06/23/2005 | US20050136032 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 06/23/2005 | US20050136005 Methods for modulation of cholesterol transport |
| 06/23/2005 | US20050136004 Biosynthesis of biodrug by inoculating an animal with a polypeptide; producing antibodies of cytokine suppressive antiinflammatory drugs; antibody is modified with polyoxyethylene glycol; inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, and psoriasis |
| 06/23/2005 | DE10352692A1 Verwendung hypo-onkotischer Lösungen in das Blut addierbarer, hyperpolymerer Hämoglobine zur Behandlung eines Lungenödems Use of hypo-oncotic solutions in the blood addierbarer, hyper hemoglobins for the treatment of pulmonary edema |
| 06/23/2005 | CA2561746A1 Methods and compounds for modulating triglyceride and vldl secretion |
| 06/23/2005 | CA2557660A1 Systems and methods related to degradation of uremic toxins |
| 06/23/2005 | CA2552435A1 Inhibitors of type 2 vascular endothelial growth factor receptors |
| 06/23/2005 | CA2549710A1 Polynucleotides and polypeptides isolated from lactobacillus rhamnosus hn001 materials incorporating them and methods for using them |
| 06/23/2005 | CA2549391A1 Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| 06/23/2005 | CA2549384A1 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 06/23/2005 | CA2549291A1 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
| 06/23/2005 | CA2549164A1 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 06/23/2005 | CA2549160A1 Treatment and preventions of asthma |
| 06/23/2005 | CA2548901A1 Use of goat blood serum derived antibodies obtained after challenge with hiv lysate for veterinary treatment |
| 06/23/2005 | CA2548822A1 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | CA2548749A1 High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers |
| 06/23/2005 | CA2548448A1 Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments |
| 06/23/2005 | CA2548310A1 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 06/23/2005 | CA2548281A1 Method of preparation of mixed phase co-crystals with active agents |
| 06/23/2005 | CA2548243A1 Integrin aiib.beta.3 specific antibodies and peptides |
| 06/23/2005 | CA2548140A1 Oligosaccharide compositions and use thereof in the treatment of infection |
| 06/23/2005 | CA2547869A1 Methods of protecting against radiation using flagellin |
| 06/23/2005 | CA2547631A1 Methods for treating inflammation using thyroid stimulating hormone |
| 06/23/2005 | CA2547621A1 Transdermal system for sustained delivery of polypeptides |
| 06/23/2005 | CA2547569A1 Recombinant factor viii having increased specific activity |